CA Patent

CA2736545A1 — Dosage units of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid

Assigned to Vertex Pharmaceuticals Inc · Expires 2010-04-01 · 16y expired

What this patent protects

The present invention relates to formulations of 3-(6-(I -(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2- yl)benzoic acid in Form I, pharmaceutical packs or kits thereof, and methods of treatment therewith.

USPTO Abstract

The present invention relates to formulations of 3-(6-(I -(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2- yl)benzoic acid in Form I, pharmaceutical packs or kits thereof, and methods of treatment therewith.

Drugs covered by this patent

Patent Metadata

Patent number
CA2736545A1
Jurisdiction
CA
Classification
—
Expires
2010-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.